About 300 reports

  • The following compounds are being studied as potential biosimilars:
  • BIOSIMILARS: MABS & BIOLOGICS PIPELINE
  • Targeted Therapy
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited

SANDOZ EXPECTS TO TAKE MARKET SHARE FROM AMGEN' S FILGRASTIM, WHICH HELD ##% OF THE US MARKET FOUR MONTHS AFTER THE LAUNCH OF ZARXIO.

  • Biosimilar
  • Targeted Therapy
  • World
  • Market Size
  • Remicade group
  • Biocon Limited - Early Stage Pipeline Products
  • Biocon Limited - Pipeline by Indication, 2016

filgrastim - Drug Profile insulin aspart - Drug Profile insulin glargine - Drug Profile Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description insulin glargine Biocon Limited NA Mylan N. V.

  • Targeted Therapy
  • India
  • World
  • Product Initiative
  • Biocon Limited
  • Branded Name
  • Monoclonal Antibody
  • Targeted Therapy
  • World
  • Market Size
  • Merck & Co., Inc.

It has received approval for tbo-filgrastim (XM## filgrastim).

  • Targeted Therapy
  • Biocon Limited
  • Hospira, Inc.
  • Mylan Inc.
  • Sandoz Inc.

filgrastim; methylprednisolone; peripheral blood stem cells; tacrolimus Northwestern University ## Oct 1999 ## Jul 2000 ## ## ## Phase I Study of CPX-##(CytarabineDaunorubicin) Liposome Injection in Patients with Advanced Hematologic Malignancies Multicenter Study of CPX-##(Cytarabine:Dauno

  • Clinical Trial
  • Drug Discovery And Development
  • Targeted Therapy
  • World
  • Product Initiative

One of the important milestones realized on this front was the FDA approval for Sandoz' s (Germany) filgrastim biosimilar-Zarxio (filgrastim-sndz)-for all five indications of the originator product-Neupogen-in 2015.

  • Targeted Therapy
  • Asia
  • Europe
  • World
  • Market Size
  • CLINICAL TRIAL PROFILE SNAPSHOTS

filgrastim; fludarabine; melphalan Scripps Health ## Mar 2005 ## Jan 2021 ## ## ## DNA Synthesis Inhibitor DNA Clinical Trial profile. ## Trial Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Biomarker(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s

  • Blood Disease
  • Targeted Therapy
  • World
  • Product Initiative
  • Alexion Pharmaceuticals, Inc.

filgrastim; leucovorin; mesna; methotrexate; thiotepa; vincristine Nationwide Children' ' s Hospital National Cancer Institute US ## Sep 2015 ## Sep 2020 ## ## ## ##.

  • Cancer
  • Targeted Therapy
  • United States
  • World
  • Product Initiative

Filgrastim in Treating Patients with Burkitt' s Lymphoma or Burkitt' s Leukemia GDCT## NCT##, U##CA##; CALGB-##; CDR## Oncology Burkitt Lymphoma, Leukemias, Lymphoma Completed Phase II Interventional allopurinol; cyclophosphamide; cytarabine; dexamethasone; doxoru

  • HIV AIDS
  • Lymphoma
  • Targeted Therapy
  • World
  • Product Initiative

filgrastim; sargramostim Fred Hutchinson Cancer Research Center ## Mar 1995 ## Oct 1997 ## ## Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Collaborato

  • Biological Therapy
  • Blood Disease
  • Targeted Therapy
  • World
  • Product Initiative

Filgrastim or Lenograstim or CSF##), Hematopoietic Progenitor Cell Antigen CD## (CD##)) Completed Phase II Interventional allogeneic bone marrow stem cells; allogeneic peripheral blood stem cells; anti-thymocyte globulin; autologous bone marrow derived stem cells; cyclophosphamide; cytarabin

  • Blood Disease
  • Cancer
  • Leukemia
  • Targeted Therapy
  • Novartis AG

filgrastim ## fludarabine anti-thymocyte globulin busulfan ## ## ## plerixafor ## Total Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2017 2017 trials are taken as of August 2017 ## CLINICAL TRIAL PROFILE SNAPSHOTS N

  • Blood Disease
  • Pathology
  • Targeted Therapy
  • World
  • Product Initiative
  • Hospira, Inc. - Phase I, 2015
  • Hospira, Inc. - Pipeline by Indication, 2015
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative
  • Hospira, Inc.
  • Clinical Trial Profile Snapshots

FILGRASTIM; FLUOROURACIL; LEUCOVORIN; METHOTREXATE; METHYLPREDNISOLONE; PENTAMIDINE ISETHIONATE; PREDNISONE; VINCRISTINE; ZIDOVUDINE THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER NATIONAL CANCER INSTITUTE ## JUN 1993 ## OCT 2005 ## ## ## DNA SYNTHESIS INHIBITOR DNA Clinical Trial profile.

  • HIV AIDS
  • Monoclonal Antibody
  • Targeted Therapy
  • World
  • Product Initiative

FILGRASTIM BIOSIMILAR, ZARXIO.

  • Targeted Therapy
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Remicade group

Verrucous Carcinoma Global Clinical Trials Review, H##, 2016 REFERENCE CODE: GDHC##CTIDB PUBLICATION DATE: DEC 2016 LIST OF TABLES LIST OF FIGURES VERRUCOUS CARCINOMA GLOBAL CLINICAL TRIALS REVIEW, H##, 2016 OUTLINES CLINICAL TRIALS IN VERRUCOUS CARCINOMA.

  • Cancer
  • Hospital
  • Targeted Therapy
  • World
  • Product Initiative

filgrastim alone or in combination have the highest number of ataxia ongoing clinical trials.

  • Neurology
  • Targeted Therapy
  • Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 22 Trial Title
  • R-CHOP [cyclophosphamide + doxorubicin + prednisone + rituximab + vincristine]

filgrastim; ifosfamide; melphalan; methotrexate; methylprednisolone; pegfilgrastim; prednisolone; rituximab; vincristine sulfate; vindesine sulfate University Hospital Essen Deutsche Krebshilfe eV ## Nov 2007 ## Mar 2017 ## ## ## ## ## DNA Synthesis Inhibitor DNA Clinical Trial profile. ##

  • Lymphoma
  • Monoclonal Antibody
  • Targeted Therapy
  • World
  • Product Initiative
  • GDCT0018652
  • Clinical Trial profile. 68 Trial Title

filgrastim; methotrexate Fondazione IRCCS - Istituto Nazionale dei Tumori Target Cytotoxic To Cells Expressing CAMPATH ## Antigen (CDw## or Cambridge Pathology ## Antigen or Epididymal Secretory Protein E## or Human Epididymis Specific Protein ## or CD##) Cells Expressing CAMPATH ## Antigen (CDw

  • Oncology
  • Targeted Therapy
  • World
  • Product Initiative
  • Celgene Corporation

filgrastim; vincristine Eastern Cooperative Oncology Group National Cancer Institute US ## Jul 1998 ## Mar 2004 ## ## ## ## A Molecular Biology And Phase II Study Of Lapatinib (GW##) In Pediatric Patients With Recurrent Or Refractory Medulloblastoma, Malignant Glioma Or Ependymoma Lapati

  • Targeted Therapy
  • Therapy
  • World
  • Product Initiative
  • F. Hoffmann-La Roche Ltd.

Binocrit (epoetin alfa Zarzio/ Zarxio (filgrastim) Used in therapy area of Hematology. neutropenia after chemotherapy.

  • Targeted Therapy
  • World
  • Market Size
  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company Limited

filgrastim; melphalan Boston Medical Center National Institutes of Health ## Nov 2000 ## Jun 2005 ## ## ## ## ## DNA Synthesis Inhibitor DNA A Multicenter Phase II Trial of Bortezomib (Velcade), Melphalan and Dexamethasone (V-MD) in Patients with Symptomatic AL-Amyloidosis or Light Chain Depo

  • Clinical Trial
  • Targeted Therapy
  • Therapy
  • World
  • Product Initiative
  • Clinical Trial Profile Snapshots

FILGRASTIM; RITUXIMAB NATIONAL CANCER INSTITUTE ## JAN 1999 ## MAR 2005 ## ## ## ## CYTOTOXIC TO CELLS EXPRESSING B LYMPHOCYTE ANTIGEN CD## (B LYMPHOCYTE SURFACE ANTIGEN B## OR BP## OR LEUKOCYTE SURFACE ANTIGEN LEU ## OR MEMBRANE SPANNING ## DOMAINS SUBFAMILY A MEMBER ## OR CD## OR MS##A##) CEL

  • Hospital
  • Lymphoma
  • Targeted Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 671 Trial Title

Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation GDCT## NCT##, Immunology Graft Versus Host Disease (GVHD) Completed Phase III Interventional

  • Drug Discovery And Development
  • Pharmaceutical
  • Targeted Therapy
  • United States
  • World

Filgrastim in Promoting Stem Cell Mobilization in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Stem Cell Transplant GDCT## NCT##, NCI-2012-##; 2008-##; P##CA## Oncology B-Cell Chronic Lymphocytic Leukemia, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma

  • Leukemia
  • Monoclonal Antibody
  • Targeted Therapy
  • World
  • Product Initiative

Cutaneous B-Cell Lymphoma Global Clinical Trials Review, H##, 2016 Reference Code: GDHC##CTIDB Publication Date: JUN 2016 LIST OF TABLES Cutaneous B-Cell Lymphoma Global Clinical Trials Review, H##, 2016 outlines clinical trials in Cutaneous B-Cell Lymphoma.

  • Cancer
  • Lymphoma
  • Targeted Therapy
  • World
  • Product Initiative

Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors GDCT## NCT##, UC-##; ##-CC-##; NCT## Immunology Hematopoiet

  • Blood Supply, Tissue Banking And Transplantation
  • Drug Discovery And Development
  • Targeted Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 89 Trial Title
  • Clinical Trial profile. 204 Trial Title
  • Lymphoma
  • Targeted Therapy
  • World
  • Product Initiative
  • Novartis AG
  • Clinical Trial profile. 443 Trial Title
  • Clinical Trial profile. 442 Trial Title

filgrastim; fludarabine phosphate; melphalan; natural killer cells; rituximab; T cell-depleted hematopoietic stem cells; thiotepa St.

  • Cancer
  • Pharmaceutical
  • Targeted Therapy
  • United States
  • World